Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Background New treatment options are needed for patients with multiple myeloma that is
refractory to proteasome inhibitors and immunomodulatory drugs. We assessed …
refractory to proteasome inhibitors and immunomodulatory drugs. We assessed …
[HTML][HTML] Clinical efficacy of daratumumab, pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among …
Introduction: Daratumumab (DARA) is a human CD38-directed monoclonal antibody,
recently approved by the FDA for treatment of myeloma patients that have received≥ 3 prior …
recently approved by the FDA for treatment of myeloma patients that have received≥ 3 prior …
[HTML][HTML] Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior …
A Chari, S Lonial, A Suvannasankha, JW Fay, B Arnulf… - Blood, 2015 - Elsevier
Introduction: Daratumumab (DARA) is a human anti-CD38 IgG1κ monoclonal antibody with
remarkable safety and activity as monotherapy in heavily treated relapsed and refractory …
remarkable safety and activity as monotherapy in heavily treated relapsed and refractory …
[HTML][HTML] Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients …
Introduction: Daratumumab is a human monoclonal antibody targeting CD38 that
demonstrated superior efficacy in combination with lenalidomide and dexamethasone (DRd) …
demonstrated superior efficacy in combination with lenalidomide and dexamethasone (DRd) …
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among …
AK Nooka, NS Joseph, JL Kaufman, LT Heffner… - Cancer, 2019 - Wiley Online Library
Background The efficacy of daratumumab (DARA) both as a monotherapy and in
combination with standard‐of‐care regimens in multiple myeloma (MM) has been …
combination with standard‐of‐care regimens in multiple myeloma (MM) has been …
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous …
P Moreau, C Hulin, A Perrot, B Arnulf, K Belhadj… - The Lancet …, 2021 - thelancet.com
Background CASSIOPEIA part 1 showed superior depth of response and significantly
improved progression-free survival with daratumumab, bortezomib, thalidomide, and …
improved progression-free survival with daratumumab, bortezomib, thalidomide, and …
Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).
8513 Background: Pts with RR MM received DARA for 9 wks in doses of 0.005-24mg/kg in
the GEN501 dose-escalation part (Lokhorst: EHA 2013 abstract S576). The purpose of the …
the GEN501 dose-escalation part (Lokhorst: EHA 2013 abstract S576). The purpose of the …
[HTML][HTML] Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with transplant …
Introduction: Daratumumab (DARA) is a human, CD38-targeting, IgG1κ monoclonal
antibody approved as monotherapy in relapsed/refractory multiple myeloma (RRMM) and in …
antibody approved as monotherapy in relapsed/refractory multiple myeloma (RRMM) and in …
Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment …
SZ Usmani, J Diels, T Ito, M Mehra… - American Journal of …, 2017 - Wiley Online Library
Daratumumab is a human CD38‐directed monoclonal antibody approved in the United
States as monotherapy for patients with multiple myeloma (MM) who have received≥ 3 prior …
States as monotherapy for patients with multiple myeloma (MM) who have received≥ 3 prior …
Phase II study of daratumumab (DARA) monotherapy in patients with≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 …
LBA8512 Background: DARA, a human anti-CD38 IgG1κ mAb, has single agent activity and
is well-tolerated in rel/ref MM (Lokhorst HM et al. ASCO 2014). This ongoing phase 2 study …
is well-tolerated in rel/ref MM (Lokhorst HM et al. ASCO 2014). This ongoing phase 2 study …